Fair Value Measurements - Additional Information (Detail) (USD $)	3 Months Ended				3 Months Ended	1 Months Ended
	Dec. 31, 2013	Sep. 30, 2013	Dec. 31, 2012	Sep. 30, 2012	Dec. 31, 2013 Ablaris Therapeutics	Jan. 31, 2011 Unidym Inc	Dec. 31, 2013 2010 Warrants	Jun. 30, 2010 2010 Warrants	Dec. 31, 2013 2012 Warrants	Dec. 31, 2012 2012 Warrants	Dec. 31, 2013 2013 Warrants
Fair Value Measurements Disclosure [Line Items]
Short term investments	$ 15,912,757	$ 9,030,261
Long-term investments	9,837,846	1,702,153
Total investments	25,750,603	10,732,414
Fair value of investments	25,533,387	10,698,271
Warrants issued to acquire Common Stock								329,649		912,543	833,530
Warrants outstanding	3,553,551						50,836		324,461		168,408
Non-cash gain (loss) from change in fair value of the derivative liability	3,519,579				12,082
Duration of exchange rights	7 years
Exchange right convertible conversion ratio for first year					0.06
Exchange right convertible conversion ratio for second year					0.04
Exchange right convertible conversion ratio for third year					0.03
Exchange right convertible conversion ratio for fourth year					0.02
Exchange right convertible conversion ratio for fifth year and beyond					0.01
Number of exchange right sold					675,000
Change in value	3,519,579				12,082
Acquisition related contingent consideration obligations	1,595,273	1,595,273	173,621	173,621
Non cash consideration received in sale of interest in subsidiary, bonds						$ 2,500,000
Bond convertible conversion price per share						$ 2.00